why choose us

First received: August 24, 2022

Clinical Trial: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

Study Status: Completed

Recruit Status: RECRUITING

Condition: Thyroid Eye Disease

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)

Brief Summary: To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

Read more